SCHEMBL28824451

SCHEMBL28824451

C=C(C(=O)OC(=O)c1ccc([N+](=O)[O-])c(F)c1)C(C)(C)C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
VCAM1 P19320 1/20 0.40
ITGB1 P05556 1/20 0.40
ITGA5 P08648 1/20 0.40
NPSR1 Q6W5P4 2/20 0.38
ALDH1A1 P00352 2/20 0.38
HPGD P15428 1/20 0.38
CTSK P43235 1/20 0.38
TSHR P16473 1/20 0.38
MAPT P10636 4/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
CASP6 P55212 1/20 0.37
TTR P02766 2/20 0.36
RAPGEF3 O95398 1/20 0.36
LMNA P02545 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28791798 0.90 ITGB1 (0.51) VCAM1ITGB1ITGA5NPSR1ALDH1A1
SCHEMBL27416551 0.86 TSHR (0.55) VCAM1ALDH1A1TSHRMAPTNPC1
SCHEMBL27832784 0.82 VCAM1 (0.55) VCAM1NPSR1ALDH1A1HPGDMAPT
SCHEMBL27448923 0.81 KMT2A (0.40) ATMVCAM1NPSR1ALDH1A1HPGD
SCHEMBL28043907 0.81 ITGB1 (0.41) ATMTDP1VCAM1ITGB1ITGA5
SCHEMBL357203 0.80 ATM (0.47) ATMTDP1VCAM1ITGB1ITGA5
SCHEMBL29966142 0.80 ATM (0.47) ATMTDP1VCAM1ITGB1ITGA5
SCHEMBL27834939 0.80 TDP1 (0.42) ATMTDP1ITGB1ITGA5ALDH1A1
SCHEMBL27487269 0.79 POLB (0.50) ATMTDP1ALDH1A1TSHRKMT2A
SCHEMBL27415134 0.79 PDK1 (0.41) VCAM1NPSR1ALDH1A1HPGDMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105164122-A Substituted oxopyridine derivatives and their use in the treatment of cardiovascular disorders Bayer Pharma AG 2015-12-16 CN disclosed